Researchers create high throughput arrays of miniaturized 3D tumor models

NewsGuard 100/100 Score

By engineering common filter papers, similar to coffee filters, a team of NYU Abu Dhabi researchers have created high throughput arrays of miniaturized 3D tumor models to replicate key aspects of tumor physiology, which are absent in traditional drug testing platforms.

With the new paper-based technology, the formed tumor models can be safely cryopreserved and stored for prolonged periods for on-demand drug testing use. These cryopreservable tumor models could provide the pharmaceutical industry with an easy and low cost method for investigating the outcomes of drug efficacy, potentially bolstering personalized medicine.

The developed technology can be transferred to other trending therapeutic applications such as measuring tumor response to drug concentration gradients, studying cancer cell signaling pathways, and investigations of invasive tumors.

The findings were published in the paper Cryopreservable Arrays of Paper-Based 3D Tumor Models for High Throughput Drug Screening, in the flagship journal, Lab on a Chip. The findings build on the team's earlier research engineering the paper platforms.

Led by Assistant Professor of Mechanical and Biomedical Engineering at NYUAD Mohammad A. Qasaimeh, the researchers sought to develop 3D tumor models because they offer great potential for understanding the fundamental mechanisms governing tumor responses to drug treatments, and provide opportunities to develop a number of emerging therapeutic applications. Currently, most pre-clinical drug screening is conducted on simplified two-dimensional (2D) monolayers of cell culture which do not fully represent the complexity of human tissues and organs.

Existing methods for developing 3D cell cultures and tumor models are laborious, technically challenging, time consuming, and do not allow cryopreservation for future use. This contributes to high attrition rates in the drug development process, and can cause significant delays to market and major financial losses to companies.

Our work presents a paper patterning method for high throughput cell culture, cryopreservation, and drug testing of 3D tumor models. This technology is very promising to provide unparalleled advantages to the fields of drug discovery, tissue engineering, and personalized medicine."

Mohammad A. Qasaimeh, Assistant Professor, Mechanical and Biomedical Engineering, NYUAD

By testing cisplatin (a typical chemotherapeutic drug) on breast cancer 3D models generated within the developed platform, they were able to prove that their technology is capable of predicting the outcomes of drug efficacy. Breast cancer is considered the most frequently diagnosed cancer in more than 80 percent worldwide. In the USA more than 10 percent of women are reported to develop invasive breast cancer over the course of their lives, and in the UAE, breast cancer is considered the most common malignancy based on incidence and mortality.

"Our reliable, easy-to-prepare, and inexpensive method is for creating high throughput paper-based arrays of 3D tumor models that will bring us one step closer to biomimetic drug screening in the pre-clinical stages," said Bisan Samara, the first author and a former research assistant in Qasaimeh's lab.

This research is an advancement of the team's earlier work, Paper-based Cell Cryopreservation, published last year in the journal Advanced Biosystems, in which they established their new technique utilizing filter paper to cryopreserve human cells, offering scientists an efficient alternative to conventional, long-term cryopreservation methods.

Source:
Journal reference:

Samara, B., et al. (2021) Cryopreservable arrays of paper-based 3D tumor models for high throughput drug screening. Lab on a Chip. doi.org/10.1039/d0lc01300e.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tumor microbiomes offer new insights for enhancing cancer therapies